Ricevi le ultime notizie sulle azioni Atara Biotherapeutics con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di ATRA

Ultime notizie per

ATARA BIOTHERAPEUTICS INC

Atara Biotherapeutics

Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics Inc

Press Releases

Atara Biotherapeutics Announces Pricing of $16 Million Offering

Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress

Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors

CDR-Life Appoints Pascal Touchon to the Board of Directors to Support Continued Growth and Advancement of Next Generation T Cell Engager Platform

Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)

Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc.

Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)

Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress

Atara Biotherapeutics Announces Changes to Its Board of Directors

ATRA

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Adverum Biotechnologies, Inc. - Common Stock

Adverum Biotechnologies

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

Anixa Biosciences

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

Coya Therapeutics

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics

InflaRx

Insight Molecular Diagnostics Inc. - Common Stock

Insight Molecular

Immunic

Opus Genetics

Kalaris Therapeutics, Inc. - Common Stock

Kalaris Therapeutics

Lite Strategy

Macrogenics

Metagenomi

Ovid Therapeutics

Sera Prognostics, Inc. - Class A Common Stock

Sera Prognostics

Spero Therapeutics

Shattuck Labs

Vistagen Therapeutics, Inc. - Common Stock

Vistagen Therapeutics

Whitehawk Therapeutics, Inc. - Common Stock

Whitehawk Therapeutics

Zentalis Pharmaceuticals, Inc. - common stock

Comments

Atara Biotherapeutics Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO